Navigation Links
Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax

Single-Dose Protection Observed Prior to or Up to 24 Hours After Exposure to Anthrax

TORONTO, Ontario, May 24, 2007 /PRNewswire/ -- Targanta Therapeutics Corporation announced today the results from a recent study demonstrating oritavancin as a potential therapy for treating exposure to Bacillus anthracis, the bacterium which causes anthrax, an acute infectious disease. Oritavancin, a novel semi- synthetic lipoglycopeptide antibiotic for the treatment of serious gram- positive infections, is Targanta's lead product currently in post-Phase 3 clinical development. This research was conducted and presented in partnership with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at the American Society for Microbiology (ASM) 107th Annual General Meeting in Toronto, Ontario from May 21-25, 2007.

"We are encouraged by the research demonstrating that oritavancin may represent a potential treatment for anthrax exposure," said Thomas Parr, Ph.D., Chief Scientific Officer, Targanta Therapeutics. "This research eventually could lead to better protection for both military personnel and citizens against an anthrax attack."

Study Methods and Results:

Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax

Using an aerosol-anthrax mouse model, researchers investigated oritavancin (ORI) as potential therapy for inhalational anthrax (post-exposure). In the model, mice were exposed to spores of the Ames strain of B. anthracis at seventy five times the lethal dose necessary to kill 50% of untreated mice (75 x LD50). The control group received either saline or 30 mg/kg of ciprofloxacin (CIP) intraperitoneally (within the abdominal cavity) every 12 hours for 14 days. ORI doses ranged from 0.1 to 30 mg/kg intraperitoneally every 48 hours for 14 days. Alternatively, ORI was administered intravenously from 5 to 50 mg/kg as a single intravenous dose. All
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the first fiscal quarter ... , Revenues of $47.5 million, up 10% over ... $0.21, up 50% over last year,s comparable quarter. ... $7.2 million, up 20% over last year,s comparable quarter. ...
(Date:7/24/2014)... 2014 IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has accepted  ... Mr. Finio has accepted a senior level finance position ... his acceptance of his new position, Mr. Finio will ... for IGI Laboratories, Inc.  The effective date of his ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
(Date:7/24/2014)... night, which shuts off nighttime production of the hormone ... widely used breast cancer drug, says a new study ... study, "Circadian and Melatonin Disruption by Exposure to Light ... Breast Cancer," published in the journal Cancer Research ... vital to the success of tamoxifen in treating breast ...
(Date:7/24/2014)... Ticket Down is a reliable source for cheap ... Sports Authority Field on July 26th. For the past four years, ... of the best club teams from around the world to North ... about weeks after its completion, fans – new and old alike ... stars in the world compete. Some of these players were already ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Four ... this month of its $3 million renovation of the ... Lokelani presidential/residential three-bedroom suites, just in time to welcome ... , With design direction from the internationally-acclaimed BraytonHughes Design ... largest on the property and the largest in Hawaii—received ...
(Date:7/24/2014)... In a July 9th article in the ... Lotus Blossom Consulting LLC , was quoted in a ... to Cut the High Cost of Infertility . Her advice ... to maximize your chance of success from the first attempt.” ... , “I am always happy to talk with the ...
(Date:7/24/2014)... County, NJ (PRWEB) July 24, 2014 ... a leading specialist in hematology and oncology, Dr. ... Medical Group. Our system welcomes Dr. Upadhyaya to ... physicians comprise CarePoint Health Medical Group, a comprehensive ... County, representing a wide range of specialties. This ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2
... claimed five more victims in Bataan, Rizal and Marikina ... from Valenzuela City and a four-and-a-half child from Balanga, ... administrator of the Amang Rodriguez Medical Center the Valenzuela ... hours after being taken there for treatment Wednesday. ...
... to combat tropical diseases that ails many millions of ... was given a renewed thrust by The Bill & ... more than $68.2 million. ,This fund will ... trypanosomiasis – which are spread by parasites and worms. ...
... Rooney, Coleen McLoughlin launched Children’s Hospice Week in the ... of the work hospices do as well as aid ... has personal experience to speak from. Her eight-year-old sister, ... a regular visitor to Claire House Children’s Hospice in ...
... review that was published in the Friday’s issue of the British ... of fractures in the later years.// ,According to the ... age of 18 years. Hence, it is expected that enhancing bone ... bone loss and osteoporosis. ,The results of 19 studies, ...
... technique to find out if metastasis from the eye cancer ... scientists at Washington University School of Medicine in St. Louis ... of the eye might spread to the liver, where it ... also of the opinion that the molecular screening test might ...
... postmenopausal women with any risk levels of breast cancer. According ... September 1 issue of Clinical Cancer Research//, Raloxifene could protect ... they are at high or low risk of developing the ... drug could reduce the risk in women with a family ...
Cached Medicine News:Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 2Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 3Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 4Health News:Raloxifene Reduces The Risk Of Breast Cancer 2Health News:Raloxifene Reduces The Risk Of Breast Cancer 3